Twinstrand Therapeutics
Burnaby
About Twinstrand Therapeutics
Twinstrand Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. The product of the company is TST10088. It is a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. Twinstrand is a Canada-based company that was founded in 1995. The company was acquired by Cangene on July 7, 2009.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $6.7M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2003)
- Website: twinstrand.com
- Phone: +1 866-300-7602
Industries & Categories
Biotechnology, Health Care, Information Technology, Medical
Canonical: https://fsome.com/organization/twinstrand-therapeutics-588523 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.